Sheila H Ridner1, Mary S Dietrich1,2, Kandace Spotanski1, Jennifer K Doersam1, Michael S Cowher3, Bret Taback4, Sarah McLaughlin5, Nicolas Ajkay6, John Boyages7, Louise Koelmeyer7, Sarah DeSnyder8, Chirag Shah9, Frank Vicini10. 1. 1 School of Nursing, Vanderbilt University , Nashville, Tennessee. 2. 2 Department of Biostatistics, Vanderbilt Ingram Cancer Center, Vanderbilt University Medical Center , Nashville, Tennessee. 3. 3 Department of Surgery, Allegheny General Hospital , Pittsburgh, Pennsylvania. 4. 4 Division of Breast Surgery, Department of Surgery, Columbia University Medical Center , New York, New York. 5. 5 Section of Surgical Oncology, Mayo Clinic , Jacksonville, Florida. 6. 6 Department of Surgical Oncology, University of Louisville , Louisville, Kentucky. 7. 7 Faculty of Medicine and Health Sciences, Macquarie University , New South Wales, Australia . 8. 8 Division of Surgery, Department of Breast Surgical Oncology, MD Anderson Cancer Center , Houston, Texas. 9. 9 Department of Radiation Oncology, Taussig Cancer Institute , Cleveland Clinic, Cleveland, Ohio. 10. 10 Michigan Healthcare Professionals, 21st Century Oncology , Farmington Hills, Michigan.
Abstract
BACKGROUND: Data regarding pretreatment, bioimpedance spectroscopy (BIS) L-Dex® values for patients newly diagnosed with breast cancer, and longitudinal data 12 months postoperatively are lacking. This study describes L-Dex values at the time of breast cancer diagnosis and maximum L-Dex change within 12 months of surgery. METHODS AND RESULTS: Patients were enrolled in a parent, clinical trial that compares the effectiveness of BIS for early detection of breast cancer-related lymphedema to tape measurement. A total of 280 women with a pretreatment and at least one postoperative L-Dex measurement (within 12 months of surgery) were included. Pretreatment L-Dex readings were compared with population norms and maximum L-Dex changes within 12 months were examined. An L-Dex U400 device was used to obtain BIS measurements. The documented normative mean value using this device is 0.00, which is at the 49th percentile for this sample. Approximately 6% of patients had a pretreatment L-Dex value of ≥7.0; 1.8% had an L-Dex value ≥10.0. For 12 months, 17.1% (n = 48) of patients had a maximum change in L-Dex value from pretreatment of ≥7.0 L-Dex units, suggestive of clinical lymphedema. CONCLUSIONS: At the time of breast cancer diagnosis, L-Dex values are similar to normative values. Identified maximum changes in L-Dex values 12 months postoperatively suggest that frequent L-Dex measurements during that time frame are of potential clinical benefit. Our findings are consistent with research supporting an L-Dex value of ≥7 as indicative of clinical lymphedema with subclinical lymphedema logically occurring at somewhat lower likely, near ≥6.5.
BACKGROUND: Data regarding pretreatment, bioimpedance spectroscopy (BIS) L-Dex® values for patients newly diagnosed with breast cancer, and longitudinal data 12 months postoperatively are lacking. This study describes L-Dex values at the time of breast cancer diagnosis and maximum L-Dex change within 12 months of surgery. METHODS AND RESULTS:Patients were enrolled in a parent, clinical trial that compares the effectiveness of BIS for early detection of breast cancer-related lymphedema to tape measurement. A total of 280 women with a pretreatment and at least one postoperative L-Dex measurement (within 12 months of surgery) were included. Pretreatment L-Dex readings were compared with population norms and maximum L-Dex changes within 12 months were examined. An L-Dex U400 device was used to obtain BIS measurements. The documented normative mean value using this device is 0.00, which is at the 49th percentile for this sample. Approximately 6% of patients had a pretreatment L-Dex value of ≥7.0; 1.8% had an L-Dex value ≥10.0. For 12 months, 17.1% (n = 48) of patients had a maximum change in L-Dex value from pretreatment of ≥7.0 L-Dex units, suggestive of clinical lymphedema. CONCLUSIONS: At the time of breast cancer diagnosis, L-Dex values are similar to normative values. Identified maximum changes in L-Dex values 12 months postoperatively suggest that frequent L-Dex measurements during that time frame are of potential clinical benefit. Our findings are consistent with research supporting an L-Dex value of ≥7 as indicative of clinical lymphedema with subclinical lymphedema logically occurring at somewhat lower likely, near ≥6.5.
Entities:
Keywords:
bioimpedance; breast cancer; detection; lymphedema
Authors: Atilla Soran; Tolga Ozmen; Kandace P McGuire; Emilia J Diego; Priscilla F McAuliffe; Marguerite Bonaventura; Gretchen M Ahrendt; Lori DeGore; Ronald Johnson Journal: Lymphat Res Biol Date: 2014-12 Impact factor: 2.589
Authors: Nicole L Stout Gergich; Lucinda A Pfalzer; Charles McGarvey; Barbara Springer; Lynn H Gerber; Peter Soballe Journal: Cancer Date: 2008-06-15 Impact factor: 6.860
Authors: María Torres Lacomba; María José Yuste Sánchez; Alvaro Zapico Goñi; David Prieto Merino; Orlando Mayoral del Moral; Ester Cerezo Téllez; Elena Minayo Mogollón Journal: BMJ Date: 2010-01-12
Authors: Lauren M Havens; Cheryl L Brunelle; Tessa C Gillespie; Madison Bernstein; Loryn K Bucci; Yara W Kassamani; Alphonse G Taghian Journal: Mhealth Date: 2021-01-20
Authors: Yara W Kassamani; Cheryl L Brunelle; Tessa C Gillespie; Madison C Bernstein; Loryn K Bucci; Tracy Nassif; Alphonse G Taghian Journal: Ann Surg Oncol Date: 2021-09-09 Impact factor: 5.344
Authors: Louise A Koelmeyer; Robert J Borotkanics; Jessica Alcorso; Philip Prah; Caleb J Winch; Kristine Nakhel; Catherine M Dean; John Boyages Journal: Cancer Date: 2018-12-06 Impact factor: 6.860
Authors: Sheila H Ridner; Chirag Shah; John Boyages; Louise Koelmeyer; Nicolas Ajkay; Sarah M DeSnyder; Sarah A McLaughlin; Mary S Dietrich Journal: Cancer Med Date: 2020-06-01 Impact factor: 4.452
Authors: Sheila H Ridner; Mary S Dietrich; Michael S Cowher; Bret Taback; Sarah McLaughlin; Nicolas Ajkay; John Boyages; Louise Koelmeyer; Sarah M DeSnyder; Jamie Wagner; Vandana Abramson; Andrew Moore; Chirag Shah Journal: Ann Surg Oncol Date: 2019-05-03 Impact factor: 5.344
Authors: Chirag Shah; April Zambelli-Weiner; Nicole Delgado; Ashley Sier; Robert Bauserman; Jerrod Nelms Journal: Breast Cancer Res Treat Date: 2020-11-27 Impact factor: 4.872